Viveve: Up as FDA approves changes to study design for urine leakage treatment

Viveve Medical

10/12/2020 14:35

** Shares of medical devices maker  VIVE.O  rise 12.3% to
$5.28 premarket
    ** VIVE says U.S. FDA approved its proposed changes to study
design of its pivotal trial testing efficacy of its
Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment for
stress urinary incontinence (SUI) in women  urn:newsml:reuters.com:*:nACS1b1Dsa
    ** Co in October had submitted protocol amendments intended
to strengthen overall study to agency
    ** Plans to initiate trial in near future
    ** SUI refers to urine leakage during moments of physical
activity increasing abdominal pressure, such as coughing and
sneezing and is most common type of urinary incontinence in
women
    ** Up to Wednesday's close, stock down 62.7% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))